Search
forLearn
5 / 801 resultslearn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
learn hibiscus
learn multipeptides
learn PTD-DBM
Research
5 / 37 resultsresearch Influence of Recombinant Codon-Optimized Plasmid DNA Encoding VEGF and FGF2 on Co-Induction of Angiogenesis
Transfected cells with VEGF and FGF2 genes improve skin wound healing by enhancing blood flow and regeneration.
research Application of genetically modified umbilical cord blood cells and direct gene therapy for treatment of skin wounds in rats
Genetically modified umbilical cord blood cells improved skin wound healing in rats.
research Трансплантация генетически модифицированных мононуклеарных клеток пуповиной крови человека и прямая генная терапия при регенерации кожных ран у крыс
Genetically modified cells improved skin wound healing in rats.
research Human umbilical cord blood mesenchymal stem cells engineered to overexpress growth factors accelerate outcomes in hair growth
Modified stem cells from umbilical cord blood can make hair grow faster.
research Migration Inhibitory Factor in Conditioned Medium from Human Umbilical Cord Blood-Derived Mesenchymal Stromal Cells Stimulates Hair Growth
Substance from human umbilical cord blood cells promotes hair growth.
Community Join
5 / 1000+ resultscommunity Are there any active Group Buys (dischord or other forums) for HMI 115?
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community Wuhan Hengheda Pharm WHP CB-03-01 Scam
The conversation is about a user who experienced negative side effects and poor sleep after using an impure hair loss treatment 'CB' from Wuhan Hengheda Pharm, which did not offer a refund or proper customer service. The user had the product tested, confirming its impurity.
community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.